WO2014088183A1 - Il-12 생산유도능을 갖는 유산균 및 그 제조 방법 - Google Patents
Il-12 생산유도능을 갖는 유산균 및 그 제조 방법 Download PDFInfo
- Publication number
- WO2014088183A1 WO2014088183A1 PCT/KR2013/006528 KR2013006528W WO2014088183A1 WO 2014088183 A1 WO2014088183 A1 WO 2014088183A1 KR 2013006528 W KR2013006528 W KR 2013006528W WO 2014088183 A1 WO2014088183 A1 WO 2014088183A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- production
- culture
- acid bacteria
- inducing ability
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Definitions
- the present invention relates to a lactic acid bacterium having IL-12 production-inducing ability and a method for producing the same.
- lactic acid bacteria have an effect of alleviating allergic symptoms or improving immune activity in addition to improving intestinal flora.
- IL-12 is an award ( ) Is a cytokine secreted from antigen-presenting cells such as cells or macrophages, and natural killer cells (NK cells), lymphokine active killer cells (LAK cells), and killer T cells (CTL cells) that directly attack cancer cells.
- NK cells natural killer cells
- LAK cells lymphokine active killer cells
- CTL cells killer T cells
- IFN- ⁇ interferon ⁇
- It also has an immunomodulatory function that shifts the Th1 / Th2 balance toward the Th1 side.
- lactic acid bacteria have a production inducing ability of this IL-12 (Patent Document 1). Oral ingestion of lactic acid bacteria directly acts on immune cells responsible for intestinal immunity, inducing IL-12 production, and thus, can promote immune resiliency and allergy symptoms.
- Patent Document 2 describes that lactic acid bacteria having a high immune activating effect are obtained by culturing lactic acid bacteria using a medium containing a corn steep liquor and a hydrolyzate of casein.
- Patent Document 3 describes that lactic acid bacteria having a high immunomodulatory effect are obtained by culturing the lactic acid bacteria in a medium of pH 3.5 to pH 5.0.
- Patent Document 1 Japanese Patent No. 4462218
- Patent Document 2 Japanese Unexamined Patent Application Publication No. 2004-41099
- Patent Document 3 International Publication No. 2007/138993
- the present inventors have diligently studied to achieve the above object, and when the neutralization culture to achieve high yield of cells in the production of lactic acid bacteria, the activity of lactic acid bacteria is reduced compared to the case of culture without pH adjustment.
- the activity of the lactic acid bacteria can be recovered or further increased, thereby completing the present invention.
- this invention provides the lactic acid bacterium which has the IL-12 production
- a method for producing a lactic acid bacterium having IL-12 production-inducing ability wherein the lactic acid bacteria are cultured while an alkali agent is added to the medium while adjusting the pH to give a stress and sterilization at the end of the culture.
- the stress is (a) culturing without addition of an alkali agent, (b) culturing at a temperature range where growth is inhibited, (c) culturing with addition of 1% by mass or more of salt, and (d A method for producing a lactic acid bacterium having IL-12 production inducing ability according to the above [1], which is at least one selected from the group consisting of culturing with a pH of 5 or less.
- [3] A method for producing a lactic acid bacterium having IL-12 production inducing ability according to the above [1] or [2], which is sterilized in a culture medium after culture and then collected.
- lactic acid bacterium is a microorganism belonging to Lactobacillus plantarum, Lactococcus lactis subspecies Cremoris, Enterococcus faecalis, or Lactobacillus brevis. 12 A method for producing lactic acid bacteria having production inducing ability.
- a lactic acid bacterium having IL-12 production-inducing ability which is obtained by culturing a lactic acid bacterium by adding an alkali agent to a medium and adjusting the pH to give a stress and sterilization at the end of the culture.
- the lactic acid bacteria of the lactic acid bacteria decayed by the neutralization culture by placing the lactic acid bacteria in an unfavorable environment for growth after the neutralization culture.
- Activity in particular, IL-12 production-inducing ability can be restored or further enhanced.
- the lactic acid bacterium which shows high activity can be manufactured, aiming at reducing manufacturing cost.
- 1 is a photograph comparing the colored state of unsterilized cells after culturing of lactic acid bacteria with the colored state of cells obtained by sterilization after sterilization under predetermined conditions.
- the lactic acid bacterium used for this invention should just be a lactic acid bacterium which has IL-12 production-inducing ability, and is not specifically limited.
- Examples include microorganisms belonging to the genus Enterococcus, such as Enterococcus faecalis and Enterococcus faecalis, Lactobacillus acidophilus, and Lactobacillus gaseri. , L.mali, L.bacillus plantarum, L.buchneri, L.buchneri, L.casei, Lactobacillus john SONii , L. gallinarum, L. amylovorus, L. amylovorus, L. brevis, Lactobacillus L.
- Lactobacillus plantarum Lactobacillus plantarum
- Lactobacillus brevis Lactobacillus brevis
- lactic acid bacteria are sufficiently grown at the front end of the culture to ensure high yield of the cells. In order to do this, it is necessary to incubate in a medium suitable for propagation of lactic acid bacteria, and at the same time, to adjust the pH by adding an alkaline agent to the medium in order to suppress a decrease in pH due to the metabolites of lactic acid bacteria (for example, lactic acid).
- aqueous solutions such as sodium hydroxide, potassium hydroxide and calcium hydroxide, ammonia and the like can be used.
- the pH is preferably maintained at pH5.8-7.5, more preferably pH6.0-6.8.
- pH adjustment may be performed manually, it is simple and accurate using a pH automatic control device (pH stat).
- the medium is not particularly limited as long as it is suitable for propagation of lactic acid bacteria.
- Suitable medium for propagation of lactic acid bacteria include a medium rich in nutrients including yeast extract, peptone, meat extract and the like.
- Commercially available media also include "Difco Lactobacilli MRS Broth” (trade name, Becton Dickinson Japan) and "MRS Buoy MERCK” (trade name, Chemicals).
- Enterococcus faecalis is maintained at pH 6.5-6.8 in a medium of ⁇ Difco Lactobacilli MRS Broth '' (trade name, Beckton Dickinson, Japan) and 16- at 35-38 ° C.
- the initial cell concentration can be increased to 1 ⁇ 10 6 to 1 ⁇ 10 7 cfu / mL until the final cell concentration is 5 ⁇ 10 9 to 5 ⁇ 10 10 cfu / mL.
- Lactobacillus plantarum (Lactobacillus plantarum) was maintained at pH 6.0-6.2 in a medium of ⁇ Difco Lactobacilli MRS Broth '' (trade name, Becton Dickinson Co., Ltd. Japan) and incubated for 18 to 40 hours at 30-35 ° C.
- the cell concentration is 1 ⁇ 10 6 to 1 ⁇ 10 7 cfu / mL, it can be grown to the final cell concentration of 5 ⁇ 10 9 to 5 ⁇ 10 10 cfu / mL.
- stress means all the environments which are undesirable for the growth of lactic acid bacteria.
- stress means all the environments which are undesirable for the growth of lactic acid bacteria.
- the lactic acid produced by the lactic acid bacteria lowers the pH of the medium, so that the lactic acid bacteria are placed at a low pH, which is undesirable for growth.
- the lactic acid bacterium is placed under a predetermined temperature, thereby making the environment undesirable for growth.
- Temperature conditions vary depending on the lactic acid bacteria used and can be appropriately set. For example, it is 3-12 degreeC from the temperature range suitable for growth, More preferably, it is the temperature range shifted to 5-10 degreeC high temperature side or low temperature side.
- the lactic acid bacterium is placed under high permeation pressure, thereby making the environment undesirable for growth.
- Salts such as NaCl are preferably added at a concentration in the culture medium so as to contain 0.5% by mass or more, more preferably 1 to 2% by mass.
- the lactic acid bacteria are placed under low pH, which makes the environment undesirable for growth.
- Acidic agents such as lactic acid, Preferably it is pH5 or less, More preferably, it adjusts to pH5-3.
- the method of stressing is not limited to what was illustrated above,
- the present invention it is also necessary to sterilize the lactic acid bacteria that have been cultured as described above. Accordingly, it is possible to prevent the self-extinguishing of the lactic acid bacteria and to ensure the stability of the quality.
- a culture is isolate
- the cells are sterilized in the culture medium after the culture and then collected.
- a method of heating and sterilizing the culture medium after culture, followed by filtration separation, centrifugation, sedimentation, and the like to remove and culture the medium may be mentioned.
- a part of the medium is removed by filtration, centrifugation, and sedimentation to prepare a concentrated solution concentrated 2 to 10 times, followed by heat sterilization, followed by filtration, centrifugation, and sedimentation. May be removed and collected. It is preferable to perform heat sterilization at 80 degreeC or more, and it is more preferable to carry out for 5 to 20 minutes at 80-100 degreeC.
- the cell of lactic acid bacteria obtained when sterilizing in the culture medium after culture
- the L * a * b * color system obtained as described below has a brightness L * value of 65 or less, and chromaticity. It is preferable to implement so that a * value may be -4 or more.
- the culture medium is sterilized in the culture solution after the culture, and the medium is removed by centrifugation, membrane separation, or sedimentation to prepare a cell concentrate having a solid content of 4 to 7%.
- the 5g is put in a 35 mm diameter quartz glass culture, and the brightness L * value and chromaticity a * value at the time of measuring the state with the L * a * b * colorimeter are calculated
- color measurement can be performed using a color difference meter.
- the lactic acid bacteria obtained by the present invention may be subjected to micronization and anti-agglomeration treatment. According to this, the activity of the lactic acid bacteria, such as the IL-12 production-inducing ability, and the stability of the quality can be maintained better.
- the method the method etc. which were described in Unexamined-Japanese-Patent No. 4212,18 are mentioned. Specifically, it can carry out as follows.
- lactic acid bacteria are pulverized or dispersed until their average particle diameter is less than 1 micron (micrometer) in nanometer (nm) size, preferably about 0.6 micron.
- distribution process may be performed separately, and can also be performed simultaneously.
- whether or not the particle size is less than 1 micron can be measured with a particle size distribution meter or an electron microscope.
- lactic acid bacteria it is preferable to carry out by a wet dispersion process. For example, 2-30 mass%, more preferably 5-20 mass% of the cells of lactic acid bacteria are contained, and the suspension adjusted to pH 6.0-7.0 is 80-pressure using a high pressure homogenizer. 200 kg / cm ⁇ 2>, More preferably, it can carry out by circulating on the conditions of 100-170 kg / cm ⁇ 2>.
- a reagglomeration prevention process is performed using a dispersing agent.
- a dispersing agent it is preferable to add a dispersing agent to the cells of lactic acid bacteria at the time of the above-mentioned micronization, to make this into fine particles, and then to powderize or to micronize the cells of lactic acid bacteria, and to add and disperse it to powder.
- Powdering can be performed by making the microbial cells of lactic acid bacteria into fine particles, followed by drying by spray drying or freeze drying.
- powdered lactic acid bacteria are dispersed in contact with the dispersing agent, so that they have good dispersibility even when resuspended in water and the like, and prevent reaggregation of the microbial cells of the lactic acid bacteria. It can keep well.
- dispersant examples include polysaccharides such as dextrin, soluble plant fiber, indigestible dextrin, low molecular sugars such as trehalose, lactose and maltose, peptides such as collagen, whey decomposition products and soy protein degradation products. . It is preferable that it is 20-1,000 mass parts of dispersing agents with respect to 100 mass parts of dry matter conversion of the cells of lactic acid bacteria, It is more preferable that it is 50-1,000 mass parts, It is most preferable that it is 100-600 mass parts.
- the amount of the dispersing agent is less than 20 parts by mass relative to 100 parts by mass of the dry matter equivalent of the cells of lactic acid bacteria, the effect of the addition of the dispersing agent is insufficient. If the amount of the dispersing agent exceeds 1,000 parts by mass, the content of the cells of the lactic acid bacteria cannot be secured.
- the lactic acid bacterium obtained by the present invention is very suitable as an active ingredient of an IL-12 production inducing agent because of its excellent IL-12 production inducing effect, as also shown in Examples described later.
- the microbial cells of the granulated lactic acid bacteria are washed with water or the like, it is not preferable because the components that are low molecular weight due to the micronization or the internal nutrient components exposed to the outside of the microorganisms may be washed away.
- a pharmaceutically acceptable base material and a carrier are added as needed, and it is a well-known formulation method, for example, it can be used as an oral preparation in the form of tablets, granules, capsules, pills, powders, liquids, powders, jellys, candies, and the like. In addition, it may be in the form of an ointment, a cream, a gel, a lotion, etc., and may be used as an external preparation for skin.
- a food raw material can also be mix
- the food raw material include various sugars, emulsifiers, sweeteners, acidulants, fruit juices, flavors, and the like. More specifically, sugars such as glucose, sucrose, fructose, honey, sugar alcohols such as sorbitol, xylitol, erythritol, lactitol and paratinit, sucrose fatty acid ester, glycerin sugar fatty acid ester, lecithin and the like Emulsifiers. In addition, you may mix
- the content of the cells of the lactic acid bacterium may be appropriately determined in consideration of the relationship between the amount of the lactic acid bacteria to be used and the effective dose, and is not particularly limited.
- a dosage form of the said IL-12 production inducer it may be taken orally in order to act in a body, or may be apply
- the dosage of the IL-12 production inducing agent is not particularly limited, but typically, when taken orally, it is approximately 0.01 to 10 g per adult in terms of dry matter of lactic acid bacteria.
- the composition and the form of these feeds can be made based on the description regarding the use form in the case of oral ingestion.
- the lactic acid bacteria obtained by the present invention can also be used in combination with food and beverages such as cookies, senbei, jelly, yokan, yogurt, manju, soft drinks, nutritional drinks, soups and the like.
- food and beverages such as cookies, senbei, jelly, yokan, yogurt, manju, soft drinks, nutritional drinks, soups and the like.
- the strain shown in Table 1 was used as lactic acid bacteria.
- Lactobacillus Lactobacillus brevis FERP BP-4693 was carried out at 31 to 32 °C, Lactic acid bacteria Lactococcus lactis subspecies Cremoris CF4 at 30 °C.
- the culture was performed by adjusting the pH to 0.1 with caustic soda using a pH automatic controller (pH stat).
- the treatment after the culturing was carried out as follows, except as specifically indicated.
- the cells were collected by centrifugation and suspended in about 20 mL of the phosphate buffer solution so that the cell concentration was 1 to 4%.
- the Teflon homogenizer was used to disperse the cells as much as possible to avoid aggregation.
- the cell suspension thus obtained was sterilized at 121 ° C. for 15 minutes, and then subjected to sonication for 30 minutes to prevent cell aggregation, and to measure the solid content of the cell suspension separately, based on the value.
- generation induction test was implemented.
- splenocytes were harvested from 8-week-old BALB / c mice, containing 10% FBS, 10 ⁇ M 2-mercaptoethanol, 10 mM HEPES, 100 U / mL penicillin, and 100 ⁇ g / mL streptomycin according to a general method.
- Cell suspension (1.0 ⁇ 10 6 cells / mL) was prepared in RPMI1640 medium.
- lactic acid bacteria were added so as to have a final concentration of 10 ⁇ g / mL in terms of dry matter, to prepare a cell / lactic acid bacteria mixed solution, and 0.2 mL of each well of a 96-hole plate was sprinkled. Cultured for 24 hours under conditions of a temperature of 37 °C, 5% CO 2, and to recover the culture supernatant after incubation was measured IL-12 content in the culture supernatant by ELISA.
- the kit "EMIL12" brand name, Thermo Scientific) was used for the measurement, and the result was calculated
- the IL-12 production-inducing ability of the cells obtained by lactic acid bacteria Lactobacillus plantarum nF1 at 32 ° C. for 20 hours and static culture was 1,800 pg / mL.
- the yield of the cells was approximately three times higher than that of the stationary culture, but the IL-12 production amount was reduced to 50 pg / mL as the IL-12 production inducing ability.
- the pH automatic control device pH stat
- the IL-12 production-inducing capacity of the cells obtained by lactic acid bacteria Lactobacillus brevis FERP BP-4693 at 31 ° C. for 29 hours was 783 pg / mL.
- the yield of the cells was approximately three times higher than that of the stationary culture, but the IL-12 production amount was reduced to 152 pg / mL as the IL-12 production inducing ability.
- the pH automatic control device pH stat
- IL-12 production-inducing ability of the cells obtained by lactic acid bacteria Lactobacillus plantarum SNK12 incubated at 32 ° C. for 24 hours was 1,050 pg / mL.
- the yield of the cells was approximately three times higher than that of the stationary culture.
- IL-12 production was reduced to 50 pg / mL as the IL-12 production-inducing ability.
- the pH automatic control device pH automatic control device
- IL-12 production-inducing ability was restored to the IL-12 production rate of 1,100 pg / mL.
- IL-12 production inducing ability was further increased by adding salt in the culture medium or raising the culture temperature to 40 ° C, which is severe for the growth of lactic acid bacteria Lactobacillus plantarum SNK12.
- the effect of activating the IL-12 production-inducing ability was the highest when the three conditions of stationary culture, salt addition, and high temperature were combined.
- lactic acid bacteria When lactic acid bacteria are supplied to the market as a preparation, it is necessary to sterilize in order to prevent self-extinguishing and the like and to ensure stability.
- a medium component is removed by MF membrane or centrifugation, and a method of sterilizing a concentrated solution suspended only in a medium such as water or a buffer solution and leaving the culture solution after the culture is left. Two methods of sterilization in advance in the state and then collecting the bacterium can be considered. Which of these methods should be adopted?
- the coloring of the cells of lactic acid bacteria was measured as follows using a color difference meter (SQ-300H manufactured by Nippon Color Industries Co., Ltd.).
- each 45 mL was dispensed into a 50 mL centrifuge tube, and the cells were collected by centrifugation at 8400 rpm for 5 minutes.
- the cells were suspended in phosphate buffer, homogenized using a Teflon homogenizer, and centrifuged again to remove the media components.
- the obtained precipitate was suspended in a phosphate buffer solution, homogenized with a Teflon homogenizer and finally prepared in a capacity of 25 mL.
- the cell suspension of 4% of the solid content prepared as described above was transferred to a quartz glass registry (35 mm diameter), and the state was changed by the color difference meter (SQ-300H manufactured by Nippon Kogyo Kogyo Co., Ltd.). Values and chromaticities a * and b * values were measured. 1 shows a photograph of the cell suspension.
- the sterilization treatment under predetermined conditions after incubation was higher than the non-sterilization, resulting in higher IL-12 production inducing ability of lactic acid bacteria.
- the sterilization temperature 80-100 degreeC is more preferable, and the fall of the brightness L * value of a cell, the increase of the chromaticity a * value, and the improvement of IL-12 production-inducing ability correlated very well.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (11)
- 유산균을 배지에 알칼리제를 첨가하여 pH를 조정하면서 배양하고, 배양 후기에 스트레스를 주고 살균하는 것을 특징으로 하는 IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 1 항에 있어서,상기 스트레스는 (a) 알칼리제를 첨가하지 않고 배양하는 것, (b) 증식이 억제되는 온도대에서 배양하는 것, (c) 배양액 중의 농도로서 1질량% 이상의 염분을 첨가하여 배양하는 것, 및 (d) pH를 5 이하로 하여 배양하는 것으로 이루어지는 군에서 선택된 적어도 하나인, IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 1 항 또는 제 2 항에 있어서,배양 후의 배양액 중에서 살균하고 그 후에 집균하는, IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서,상기 유산균은 식물로부터 분리된 것인, IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서,상기 유산균은 락토바실러스 플란타룸, 락토코커스 락티스 아종 크레모리스, 엔테로코커스 패칼리스, 또는 락토바실러스 브레비스에 속하는 미생물인, IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 1 항 내지 제 5 항 중 어느 한 항에 있어서,상기 살균을 80℃ 이상에서 실시하는 IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 제 3 항에 있어서,배양 후의 배양액 중에서 살균하고, 그것을 원심분리하거나, 막분리하거나, 또는 침강시킴으로써 배지를 제거하고 조제한 고형분 4~7%의 균체 농축액 5g을 직경 35mm의 석영 유리 샬레에 넣고, 그 상태로 L*a*b* 표색계의 측색을 측정했을 때의 명도 L*값이 65 이하이며, 색도 a*값이 -4 이상이 되도록 해당 살균을 실시하는 IL-12 생산유도능을 갖는 유산균의 제조 방법.
- 유산균을 배지에 알칼리제를 첨가하여 pH를 조정하면서 배양하고, 배양 후기에 스트레스를 주고 살균하여 얻어진 것인 것을 특징으로 하는 IL-12 생산유도능을 갖는 유산균.
- 제 8 항에 있어서,배양 후의 배양액 중에서 살균하고 그 후에 집균하여 얻어진 것인, IL-12 생산유도능을 갖는 유산균.
- 제 8 항 또는 제 9 항에 있어서,80℃ 이상에서 살균하여 얻어진 것인, IL-12 생산유도능을 갖는 유산균.
- 제 9 항에 있어서,배양 후의 배양액 중에서 살균하고, 그것을 원심분리하거나, 막분리하거나, 또는 침강시킴으로써 배지를 제거하고 조제한 고형분 4~7%의 균체 농축액 5g을 직경 35mm의 석영 유리 샬레에 넣고, 그 상태로 L*a*b* 표색계의 측색을 측정했을 때의 명도 L*값이 65 이하이며, 색도 a*값이 -4 이상이 되도록 해당 살균을 실시하여 얻어진 것인 IL-12 생산유도능을 갖는 유산균.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK13860196.8T DK2930235T3 (da) | 2012-12-07 | 2013-07-22 | Lactobacillus sp. med evne til at inducere IL-12 produktion, og fremgangsmåde til dyrkning af samme |
KR1020137034003A KR101583018B1 (ko) | 2012-12-07 | 2013-07-22 | Il-12 생산유도능을 갖는 유산균 및 그 제조 방법 |
ES13860196T ES2873951T3 (es) | 2012-12-07 | 2013-07-22 | Lactobacillus que tiene la capacidad de inducir la producción de IL-12 y método para cultivar el mismo |
CN201380072367.8A CN105026549B (zh) | 2012-12-07 | 2013-07-22 | 具有诱导il-12产生的能力的乳酸杆菌以及用于培养其的方法 |
EP13860196.8A EP2930235B1 (en) | 2012-12-07 | 2013-07-22 | Lactobacillus having ability to induce il-12 production, and method for culturing same |
US14/650,341 US20150344841A1 (en) | 2012-12-07 | 2013-07-22 | Lactobacillus having ability to induce il-12 production, and method for culturing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012267793 | 2012-12-07 | ||
JP2012-267793 | 2012-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014088183A1 true WO2014088183A1 (ko) | 2014-06-12 |
Family
ID=50883583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/006528 WO2014088183A1 (ko) | 2012-12-07 | 2013-07-22 | Il-12 생산유도능을 갖는 유산균 및 그 제조 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150344841A1 (ko) |
EP (1) | EP2930235B1 (ko) |
JP (1) | JP2014131504A (ko) |
KR (1) | KR101583018B1 (ko) |
CN (1) | CN105026549B (ko) |
DK (1) | DK2930235T3 (ko) |
ES (1) | ES2873951T3 (ko) |
WO (1) | WO2014088183A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016136890A (ja) * | 2015-01-28 | 2016-08-04 | 株式会社ヤクルト本社 | 乳酸菌のインターロイキン10産生誘導能の増強方法 |
KR102258914B1 (ko) * | 2016-07-29 | 2021-06-02 | 바이오제닉스코리아 주식회사 | 항균 마스크 |
JP6649920B2 (ja) * | 2016-08-05 | 2020-02-19 | 有限会社バイオ研 | 免疫調節用組成物、免疫調節用組成物の製造のための使用、免疫調節用組成物の製造方法、該免疫調節用組成物を用いる食品、医薬品、動物食餌製品の製造方法 |
CN106222125B (zh) * | 2016-09-14 | 2018-10-23 | 光明乳业股份有限公司 | 一种植物乳杆菌增殖剂及其应用 |
KR101794635B1 (ko) * | 2016-11-30 | 2017-11-07 | 주식회사 락토메이슨 | 막 필터를 이용한 고농도 사균의 제조방법 및 이의 제조방법으로 제조된 사균 |
JP6298912B1 (ja) * | 2017-04-10 | 2018-03-20 | 有限会社バイオ研 | 乳酸菌の製造方法、及び免疫調節用組成物 |
KR20230085967A (ko) | 2021-12-07 | 2023-06-15 | 한전건 | 나노이온 클러스터 공정으로 코팅한 항균 생리대 |
CN116650615B (zh) * | 2023-07-28 | 2023-11-03 | 北京盛美诺生物技术有限公司 | 一种具有口腔护理功效的组合物及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004041099A (ja) | 2002-07-12 | 2004-02-12 | Combi Corp | 免疫賦活効果を有する乳酸菌の製造法及び免疫賦活剤 |
KR20070078107A (ko) * | 2006-01-25 | 2007-07-31 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
KR20070110115A (ko) * | 2005-03-03 | 2007-11-15 | 메이지 데어리즈 코포레이션 | 면역기능 조정제 |
WO2007138993A1 (ja) | 2006-05-31 | 2007-12-06 | Meiji Dairies Corporation | 免疫調節活性の高い乳酸菌の培養法 |
JP2010132579A (ja) * | 2008-12-02 | 2010-06-17 | Snow Brand Milk Prod Co Ltd | 免疫調節機能を有する乳酸菌 |
JP4621218B2 (ja) | 2007-02-09 | 2011-01-26 | 有限会社バイオ研 | Th1誘導剤及びその製造方法 |
KR20110009560A (ko) * | 2009-07-22 | 2011-01-28 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006028047A (ja) * | 2004-07-14 | 2006-02-02 | Kikkoman Corp | インターロイキン12産生促進剤およびその製造法 |
TW200637908A (en) * | 2005-01-04 | 2006-11-01 | Calpis Co Ltd | Method for preparation of lactic acid bacterium having anti-allergic activity |
CA2737429C (en) * | 2008-09-16 | 2014-10-28 | Mitsui Chemicals, Inc. | Method for producing lactic acid from plant-derived raw material, and lactic-acid-producing bacterium |
JP2010095465A (ja) * | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | 乳酸菌含有免疫賦活用組成物 |
EP2412797B1 (en) * | 2009-03-24 | 2018-01-17 | Suntory Holdings Limited | Method for producing lactic acid bacteria having enhanced immunomodulating activities |
-
2013
- 2013-07-22 CN CN201380072367.8A patent/CN105026549B/zh active Active
- 2013-07-22 WO PCT/KR2013/006528 patent/WO2014088183A1/ko active Application Filing
- 2013-07-22 KR KR1020137034003A patent/KR101583018B1/ko active IP Right Grant
- 2013-07-22 ES ES13860196T patent/ES2873951T3/es active Active
- 2013-07-22 US US14/650,341 patent/US20150344841A1/en not_active Abandoned
- 2013-07-22 DK DK13860196.8T patent/DK2930235T3/da active
- 2013-07-22 EP EP13860196.8A patent/EP2930235B1/en active Active
- 2013-11-29 JP JP2013247044A patent/JP2014131504A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004041099A (ja) | 2002-07-12 | 2004-02-12 | Combi Corp | 免疫賦活効果を有する乳酸菌の製造法及び免疫賦活剤 |
KR20070110115A (ko) * | 2005-03-03 | 2007-11-15 | 메이지 데어리즈 코포레이션 | 면역기능 조정제 |
KR20070078107A (ko) * | 2006-01-25 | 2007-07-31 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
WO2007138993A1 (ja) | 2006-05-31 | 2007-12-06 | Meiji Dairies Corporation | 免疫調節活性の高い乳酸菌の培養法 |
KR20090024175A (ko) * | 2006-05-31 | 2009-03-06 | 메이지 데어리즈 코포레이션 | 면역조절 활성이 높은 유산균의 배양법 |
JP4621218B2 (ja) | 2007-02-09 | 2011-01-26 | 有限会社バイオ研 | Th1誘導剤及びその製造方法 |
JP2010132579A (ja) * | 2008-12-02 | 2010-06-17 | Snow Brand Milk Prod Co Ltd | 免疫調節機能を有する乳酸菌 |
KR20110009560A (ko) * | 2009-07-22 | 2011-01-28 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2930235A4 |
Also Published As
Publication number | Publication date |
---|---|
ES2873951T3 (es) | 2021-11-04 |
CN105026549A (zh) | 2015-11-04 |
CN105026549B (zh) | 2021-03-16 |
KR101583018B1 (ko) | 2016-01-06 |
KR20140088501A (ko) | 2014-07-10 |
EP2930235A1 (en) | 2015-10-14 |
US20150344841A1 (en) | 2015-12-03 |
EP2930235B1 (en) | 2021-03-10 |
JP2014131504A (ja) | 2014-07-17 |
DK2930235T3 (da) | 2021-06-07 |
EP2930235A4 (en) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014088183A1 (ko) | Il-12 생산유도능을 갖는 유산균 및 그 제조 방법 | |
KR101108428B1 (ko) | 인간의 모유에서 분리한 프로바이오틱 활성 및 체중 증가억제 효과를 갖는 유산균 | |
WO2012060579A2 (ko) | 항균용 유산균 사균체 및 이의 제조방법 | |
ES2231908T3 (es) | Cepas novedosas de lactobacilos utiles en el tratamiento de trastornos del aparato digestivo. | |
WO2014007427A1 (ko) | 효소전환과 유산균 발효를 이용한 화합물 k의 함량이 강화된 발효홍삼 농축액의 제조방법 및 그 제조방법에 의해 제조된 발효홍삼 농축액을 유효성분으로 함유하는 제품 | |
EP2634269A1 (en) | New strain of lactic acid bacteria and its combinations producing probiotic preparations | |
EP1189517B1 (fr) | Procede de preparation d'un produit lacte immunostimulant et ses applications | |
CN108783462A (zh) | 一种肠道益生菌制剂的工业生产方法 | |
WO2016186245A1 (ko) | 성장 촉진을 위한 비피도박테리움 롱굼 cbt bg7 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 | |
KR20060135016A (ko) | 유카 추출물, 퀼라야 추출물 및 유산균을 포함하는 조성물및 상기 조성물을 함유하는 음식물 | |
KR101611834B1 (ko) | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 락토바실루스 플란타룸 cbt lp3 균주 및 이를 포함하는 조성물 | |
KR100812806B1 (ko) | 식이요법제, 건강보조식품 또는 약학 제품으로서 사용하기위한 알칼리성 스핑고마이엘리나제 함유 조성물 | |
TWI689585B (zh) | 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑 | |
WO2016186243A1 (ko) | 신규한 비피더스 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 | |
KR20230095039A (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2018030730A1 (ko) | 락토바실러스 살리바리우스 cjls1511, 상기 균 또는 이의 사균체를 포함하는 동물 사료 첨가제 조성물, 및 상기 사균체의 제조 방법 | |
KR20180129168A (ko) | 유산균 함유 천연 리포좀, 그 제조방법 및 이를 포함하는 식품 또는 약학 조성물 | |
WO2017026635A1 (ko) | 신규한 락토바실러스 속 미생물 및 이를 포함하는 동물 사료용 조성물 | |
TW201722446A (zh) | 適合乳兒之抗過敏劑 | |
WO2004009800A1 (ja) | ラクトバシラス・カゼイ 亜種 カゼイ増殖促進用組成物 | |
WO2021242057A1 (ko) | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
WO2021242056A1 (ko) | 비피도박테리움 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
EP2545930A1 (en) | Agent for controlling the increase and decrease of lactobacillus bifidus in colon | |
WO2013151363A1 (ko) | 신규 분리한 바실러스 리체니포미스 및 이를 이용한 프로바이오틱스 | |
JP2018174772A (ja) | 乳酸菌の製造方法、及び免疫調節用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380072367.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20137034003 Country of ref document: KR Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13860196 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201503387 Country of ref document: ID |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14650341 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013860196 Country of ref document: EP |